PH12019501885A1 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
PH12019501885A1
PH12019501885A1 PH12019501885A PH12019501885A PH12019501885A1 PH 12019501885 A1 PH12019501885 A1 PH 12019501885A1 PH 12019501885 A PH12019501885 A PH 12019501885A PH 12019501885 A PH12019501885 A PH 12019501885A PH 12019501885 A1 PH12019501885 A1 PH 12019501885A1
Authority
PH
Philippines
Prior art keywords
film
plates
panels
relates
cancer treatment
Prior art date
Application number
PH12019501885A
Other languages
English (en)
Inventor
Kim Stuyckens
Ruixo Juan Jose Perez
Porre Peter Marie Z De
Anjali Narayan Avadhani
Yohann Loriot
Arlene O Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12019501885(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PH12019501885A1 publication Critical patent/PH12019501885A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
PH12019501885A 2017-02-06 2019-08-05 Cancer treatment PH12019501885A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
PH12019501885A1 true PH12019501885A1 (en) 2020-06-29

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019501885A PH12019501885A1 (en) 2017-02-06 2019-08-05 Cancer treatment

Country Status (26)

Country Link
US (2) US11077106B2 (https=)
EP (2) EP4286005A3 (https=)
JP (3) JP2020505425A (https=)
KR (2) KR20250069693A (https=)
CN (1) CN110198716A (https=)
AU (2) AU2018216969B2 (https=)
BR (1) BR112019016043A2 (https=)
CA (1) CA3049737A1 (https=)
DK (1) DK3576740T3 (https=)
ES (1) ES2953005T3 (https=)
FI (1) FI3576740T3 (https=)
HR (1) HRP20230697T1 (https=)
HU (1) HUE062453T2 (https=)
IL (1) IL268463A (https=)
JO (1) JOP20190190B1 (https=)
LT (1) LT3576740T (https=)
MX (2) MX2019009304A (https=)
NZ (2) NZ755301A (https=)
PH (1) PH12019501885A1 (https=)
PL (1) PL3576740T3 (https=)
RS (1) RS64778B1 (https=)
SG (2) SG10202105110VA (https=)
SI (1) SI3576740T1 (https=)
SM (1) SMT202300233T1 (https=)
TW (1) TWI874925B (https=)
UA (1) UA126336C2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
EP3923942A1 (en) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Cancer treatment
PH12021552342A1 (en) * 2019-03-29 2022-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MA55486A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
CN115103678A (zh) * 2020-02-12 2022-09-23 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症(covid-19)の予防または治療剤および医薬組成物
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése

Also Published As

Publication number Publication date
DK3576740T3 (da) 2023-07-24
TW202402290A (zh) 2024-01-16
JP2025024064A (ja) 2025-02-19
AU2024201871B2 (en) 2026-02-26
US20200022976A1 (en) 2020-01-23
NZ755301A (en) 2025-12-19
HRP20230697T1 (hr) 2023-10-13
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
ES2953005T3 (es) 2023-11-07
LT3576740T (lt) 2023-08-10
IL268463A (en) 2019-09-26
KR20250069693A (ko) 2025-05-19
EP4286005A3 (en) 2024-03-06
EP4286005A2 (en) 2023-12-06
MX2019009304A (es) 2019-09-19
JP7668777B2 (ja) 2025-04-25
SMT202300233T1 (it) 2023-09-06
US11077106B2 (en) 2021-08-03
TWI874925B (zh) 2025-03-01
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
CA3049737A1 (en) 2018-08-09
MX2022007955A (es) 2022-07-27
CN110198716A (zh) 2019-09-03
AU2018216969A1 (en) 2019-07-25
HUE062453T2 (hu) 2023-11-28
JOP20190190A1 (ar) 2019-08-04
KR20190110581A (ko) 2019-09-30
JP2020505425A (ja) 2020-02-20
BR112019016043A2 (pt) 2020-03-31
SG10202105110VA (en) 2021-06-29
RS64778B1 (sr) 2023-11-30
EP3576740B1 (en) 2023-06-14
EP3576740A1 (en) 2019-12-11
PL3576740T3 (pl) 2023-09-11
FI3576740T3 (fi) 2023-08-31
JOP20190190B1 (ar) 2024-04-18
NZ796822A (en) 2025-12-19
AU2018216969B2 (en) 2024-04-11
AU2024201871A1 (en) 2024-04-11
SI3576740T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
PH12019501885A1 (en) Cancer treatment
UA111530C2 (uk) Пластикова панель пвх
EA201991148A1 (ru) Половая панель и способ для производства половой панели
MX2022011263A (es) Elemento de recubrimiento de superficie decorativo, elemento de recubrimiento de superficie y procedimiento para producir un elemento de recubrimiento superficial decorativo.
MX2022008033A (es) Elemento de revestimiento de superficie decorativo, revestimiento de elemento de revestimiento de superficie, y procedimiento para producir dicho elemento de revestimiento de superficie decorativo.
EA202191572A1 (ru) Декоративная панель и декоративное напольное покрытие, состоящее из указанных панелей
EA202191590A1 (ru) Декоративная панель и декоративное напольное покрытие, состоящее из указанных панелей
MX2021001630A (es) Placa de yeso hecha de yeso que tiene un alto nivel de sal de cloruro y una lamina perforada y metodos asociados con esta.
MX2023012809A (es) Tienda modular.
ATE447495T1 (de) Fussboden-, wand- oder deckenpaneele sowie verfahren zu deren herstellung
MX2019004908A (es) Metodo para producir un panel de pared o piso decorado.
MX2024007292A (es) Panel decorativo y metodo para producir dicho panel.
EA202191573A1 (ru) Декоративная панель и декоративное напольное покрытие, состоящее из указанных панелей
WO2016044858A3 (en) Wall panel
MY208310A (en) Use of bis(2-ethylhexyl) cyclohexane-1,4-dicarboxylate as plasticizer in surface coverings
TW200627519A (en) Substrate processing system
PL4221979T3 (pl) Panel, w szczególności panel podłogowy, sufitowy lub ścienny; pokrycie zbudowane z wielu takich paneli; i sposób recyklingu takiego panelu
EP4032920A4 (en) Method for manufacturing vinyl chloride-acryl copolymer latex
CN309771813S (zh) 暗装淋浴装饰板
JP1751785S (ja) 建物用枠付き戸
JP1751784S (ja) 建物用枠付き引戸
TR201920992A2 (tr) Konsol bağlanti aparati
CA183822S (en) Printed sheet for construction panel
ZA202200052B (en) Fireproof polystyrene board and method for producing the same
CA177302S (en) Printed sheet for construction panel